Vanda Pharmaceuticals Inc. (VNDA)
NASDAQ: VNDA · Real-Time Price · USD
4.855
-0.285 (-5.54%)
Nov 20, 2025, 3:51 PM EST - Market open
Vanda Pharmaceuticals Revenue
Vanda Pharmaceuticals had revenue of $56.26M in the quarter ending September 30, 2025, with 18.06% growth. This brings the company's revenue in the last twelve months to $212.07M, up 11.12% year-over-year. In the year 2024, Vanda Pharmaceuticals had annual revenue of $198.77M with 3.18% growth.
Revenue (ttm)
$212.07M
Revenue Growth
+11.12%
P/S Ratio
1.42
Revenue / Employee
$576,288
Employees
368
Market Cap
286.91M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 198.77M | 6.13M | 3.18% |
| Dec 31, 2023 | 192.64M | -61.74M | -24.27% |
| Dec 31, 2022 | 254.38M | -14.30M | -5.32% |
| Dec 31, 2021 | 268.68M | 20.51M | 8.27% |
| Dec 31, 2020 | 248.17M | 20.98M | 9.23% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
VNDA News
- 2 days ago - Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients - Benzinga
- 2 days ago - Vanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting - PRNewsWire
- 14 days ago - Vanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference - PRNewsWire
- 21 days ago - Vanda Pharmaceuticals Inc. (VNDA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Vanda Pharmaceuticals Reports Third Quarter 2025 Financial Results - PRNewsWire
- 4 weeks ago - Vanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025 - PRNewsWire
- 6 weeks ago - Monumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena - PRNewsWire
- 7 weeks ago - Vanda Pharmaceuticals Announces Collaborative Framework for Resolution of Disputes with the U.S. Food and Drug Administration - PRNewsWire